Cognitive evolution in natalizumab-treated multiple sclerosis patients

BACKGROUND: Cognitive dysfunction affects up to 65% of multiple sclerosis (MS) patients and progresses over time. Natalizumab has been shown to be superior to placebo in preserving cognition for the first two years of therapy. OBJECTIVES: The objectives of this study are to understand the impact of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacques, Francois H, Harel, Brian T, Schembri, Adrian J, Paquette, Chantal, Bilodeau, Brigitte, Kalinowski, Pawel, Roy, Reshmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408753/
https://www.ncbi.nlm.nih.gov/pubmed/28607732
http://dx.doi.org/10.1177/2055217316657116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408753/
https://www.ncbi.nlm.nih.gov/pubmed/28607732
http://dx.doi.org/10.1177/2055217316657116

Ejemplares similares